Report Highlights

U.S. Nasal Mucosa Drug Delivery: Market Overview

The U.S. nasal mucosa drug supply device market is a mature but rapidly evolving segment, valued at USD 1.82 billion in 2024, structured around three primary product categories: liquid nasal spray systems, powder dispersion devices, and pressurized metered-dose nasal inhalers. Government regulation has been the dominant force shaping commercialization pathways, as the FDA classifies most nasal delivery devices combined with drug formulations as combination products under 21 CFR Part 3, requiring coordinated review by the Center for Drug Evaluation and Research (CDER) and the Center for Devices and Radiological Health (CDRH). This dual-center oversight has historically created complex approval dynamics that favor well-resourced incumbents.

The private sector has led innovation in device engineering — particularly actuator design, dose-metering accuracy, and patient-interface ergonomics — while the federal government has defined the clinical evidence thresholds that determine market entry. The COVID-19 pandemic accelerated interest in nasal delivery as a needle-free vaccination and antiviral administration route, drawing venture capital into startups such as Liqtech Pharma and Bioxcel Therapeutics, which are advancing nasal delivery of CNS-active compounds. The market is concentrated among Aptar Pharma, BD, and Johnson & Johnson, which together control an estimated 58% of the device supply segment by volume.

Policy-Driven Growth in U.S. Nasal Drug Delivery Devices

Three specific policy mechanisms are directly driving demand in this market. First, the FDA's landmark approval of Narcan (naloxone) nasal spray as an over-the-counter drug in March 2023 under the nonprescription drug approval framework — enabled by the Omnibus Appropriations Act of 2023 — created a mass-market consumer channel that did not previously exist for nasal drug-device combinations. Emergent BioSolutions and Harm Reduction Therapeutics are now supplying OTC naloxone devices through retail and government procurement channels, with SAMHSA allocating USD 1.5 billion under the Consolidated Appropriations Act of 2023 for opioid response, a significant portion directed at naloxone device procurement. This single policy action expanded the addressable device market by an estimated USD 280 million annually.

Second, the BARDA (Biomedical Advanced Research and Development Authority) medical countermeasure programme under the Public Health Service Act (42 U.S.C. § 247d-7e) has funded development of nasal delivery platforms for emergency use, including aerosolized antiviral and nerve agent antidote devices, with active contracts exceeding USD 190 million through 2026. Third, the FDA's Draft Guidance on Nasal Spray and Inhalation Solution Drug Products issued for industry review establishes bioequivalence standards that, once finalized, will mandate device-specific in vitro performance testing — a compliance requirement that will accelerate replacement cycles across hospital and pharmacy formularies and drive new device procurement across the forecast period.

Regulatory Barriers and Compliance Costs

The primary regulatory barrier in this market is the combination product designation process administered under 21 CFR Part 3 by FDA's Office of Combination Products (OCP). Companies must submit a Request for Designation (RFD) that can take up to 60 days to adjudicate, and the subsequent review pathway — either NDA or PMA — adds 12 to 36 months to commercialization timelines depending on classification. Device-only nasal delivery systems must additionally comply with Quality System Regulation under 21 CFR Part 820 and, from late 2025, with the updated Quality Management System Regulation (QMSR), which aligns with ISO 13485 and introduces new process validation documentation requirements that smaller device manufacturers estimate will cost USD 800,000 to USD 2.1 million per product line to implement.

A second major barrier is the FDA's bioequivalence framework for nasal spray drug products, which requires demonstration of in vitro equivalence across actuation force, spray pattern, droplet size distribution, and delivered dose uniformity. CDER's Office of Pharmaceutical Quality administers these requirements, and a complete response letter for bioequivalence deficiencies can add 18 to 24 months to an ANDA submission timeline. Additionally, EPA regulations under the Clean Air Act restrict propellant choices for pressurized nasal devices, effectively prohibiting high-GWP hydrofluorocarbon propellants and requiring reformulation to HFA-134a or propellant-free systems — a transition that Seaspray Pharma and AstraZeneca have each reported costs exceeding USD 5 million per affected SKU.

Policy-Created Opportunities in U.S. Nasal Drug Delivery

The most immediately actionable opportunity is BARDA's ongoing solicitation under Broad Agency Announcement BARDA-RFP-2024-100, which seeks nasal delivery platforms suitable for nerve agent antidotes including atropine and pralidoxime in emergency auto-injector replacement formats. Awards under this programme are expected between Q2 and Q4 2026, with contract values ranging from USD 15 million to USD 75 million per selected developer. Simultaneously, the Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) is separately evaluating nasal atomization devices for battlefield trauma analgesic delivery, with a procurement decision anticipated in 2027.

A second structural opportunity is created by the FDA's 2023 update to its Guidance for Industry on Pediatric Drug Development, which prioritizes needle-free delivery routes — explicitly including nasal — for CNS, analgesic, and anti-emetic drugs in pediatric populations. Manufacturers that achieve 505(b)(2) approvals for pediatric-indicated nasal formulations before 2027 qualify for six months of additional market exclusivity under the Best Pharmaceuticals for Children Act (BPCA), a provision that significantly improves return on development investment. Companies including Teleflex and Bespak are already repositioning nasal atomization product lines to target pediatric emergency medicine applications in anticipation of these incentives taking full commercial effect.

Market at a Glance

Leading Market Participants

• Aptar Pharma
• BD (Becton, Dickinson and Company)
• Johnson & Johnson
• Teleflex
• Impel Pharmaceuticals
• Emergent BioSolutions
• AstraZeneca (nasal device division)
• Bespak (a Consort Medical company)
• Liqtech Pharma
• Harm Reduction Therapeutics

Regulatory and Policy Environment

The foundational legislation governing this market is the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Medical Device Amendments of 1976 and the Drug-Device Combination Product provisions codified under 21 U.S.C. § 353(g). CDER holds primary jurisdiction over nasal drug-device combinations where the drug constituent is the primary mode of action, while CDRH governs standalone nasal delivery device platforms. The FDA's Office of Combination Products issued its final guidance, "Classification of Products as Drugs and Devices and Additional Product Classification Issues," which remains the operative framework for assignment decisions. Upcoming regulatory changes include the mandatory QMSR compliance deadline of February 2026, which will require all Class II nasal device manufacturers to update design control and risk management documentation to ISO 14971:2019 standards — a transition the FDA has indicated will not be subject to enforcement discretion extensions.

Compared to regional peers, the U.S. framework is notably more burdensome at the combination product classification stage but offers faster post-designation review timelines than the EU Medical Device Regulation (MDR 2017/745) notified body process, which currently averages 26 months for Class III combination products. The U.S. 505(b)(2) pathway — unavailable in the EU — represents a structural regulatory advantage for nasal drug-device innovators targeting the American market first. The FDA's ongoing Prescription Drug User Fee Act (PDUFA VII) commitments, effective through fiscal year 2027, include performance goals requiring CDER to complete 90% of standard NDA reviews within 12 months, directly benefiting nasal combination product applicants and compressing go-to-market timelines relative to competing geographies.

Long-Term Policy Outlook for U.S. Nasal Drug Delivery Devices

By 2032, the most consequential anticipated policy change is the FDA's expected finalization of its revised Guidance on Nasal Spray Drug Products: Chemistry, Manufacturing, and Controls Documentation, which will for the first time establish standardized device performance specifications as binding elements of NDA submissions rather than advisory recommendations. This shift will effectively mandate device qualification studies as a prerequisite for approval, increasing development costs for new entrants by an estimated 20 to 35% but simultaneously raising barriers against generic device substitution — a net benefit for branded combination product holders. Additionally, CMS is expected to expand reimbursement codes under HCPCS Level II to include specific nasal drug delivery device categories by 2028, enabling direct billing by home health agencies and expanding the addressable market beyond hospital-dispensed settings.

Legislative momentum behind the VALID Act — which, if enacted, will bring Laboratory Developed Tests and certain digital dose-tracking components of smart nasal devices under FDA oversight — will also reshape device feature requirements by 2030. Sensor-enabled nasal delivery devices that log actuation data for remote monitoring will require 510(k) clearance for their digital components under the proposed framework, creating both a compliance burden and a product differentiation opportunity for manufacturers that achieve early clearance. The broader policy trajectory strongly favors integrated drug-device-digital platforms, and manufacturers that align R&D investment with the FDA's Digital Health Center of Excellence roadmap before 2027 will be best positioned to capture the premium-price segments that dominate the post-2029 market landscape.